Cargando…

KRasG12C inhibitors in clinical trials: a short historical perspective

KRas is the most frequently mutated oncogene in human cancer, and even 40 years after the initial discovery of Ras oncogenes in 1982, no approved drug directly targets Ras in Ras-driven cancer. New information and approaches for direct targeting of mutant Ras have fueled hope for the development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Goebel, Lisa, Müller, Matthias P., Goody, Roger S., Rauh, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549139/
https://www.ncbi.nlm.nih.gov/pubmed/33479673
http://dx.doi.org/10.1039/d0md00096e

Ejemplares similares